In this connection, Accenture will use Google Cloud as the cloud technology provider for its INTIENT life sciences industry platform. The new, multi-year partnership will see Google’s cloud
The MAA is supported by data from the single arm, open-label, Phase 2 ZUMA-2 trial, which demonstrated an overall response rate of 93 percent, including 67 percent with
The deals are being carried out to help in facilitating the closing of the previously announced $63bn acquisition of Allergan by AbbVie. Brazikumab is an investigational IL-23 inhibitor,
In patients on stable background PAH-specific therapies, sotatercept demonstrated a statistically significant reduction in pulmonary vascular resistance (PVR), the trial’s primary endpoint, at week 24 versus placebo. The
DS-8201 is trastuzumab deruxtecan in Japan and other regions of world barring the US where it is fam-trastuzumab deruxtecan-nxki. The mid-stage trial for the ADC was held in
XERMELO is approved for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy, but is not currently
LB-102 is a novel benzamide designed to be an improved version of amisulpride, a drug successfully used in Europe but unavailable in the United States. The ongoing study
TEPEZZA is the first and only FDA-approved medicine for the treatment of TED, a serious, progressive and vision-threatening rare autoimmune disease that is associated with proptosis (eye bulging),
The patient had travelled from Wuhan to Washington. The novel coronavirus infection is believed to have originated at a seafood wholesale market in the Chinese city in Hubei
The approval for Mayzent from the European Commission (EC) is for SPMS with active disease, confirmed by relapses or imaging features of inflammatory activity. The sphingosine 1-phosphate receptor
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.